CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: A gynecologic oncology group study

Cancer

Volumn 115, Issue 7, 2009, Pages 1395-1403

  Tian, Chunqiao ^a   Markman, Maurie ^b   Zaino, Richard ^c   Ozols, Robert F ^d   McGuire, William P ^e   Muggia, Franco M ^f   Rose, Peter G ^g   Spriggs, David ^h   Armstrong, Deborah K ⁱ  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e Franklin Square Hospital Center   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CA 125; Clear cell cancer; Mucinous cell cancer; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CELL TYPE; CLEAR CELL CARCINOMA; CLINICAL ASSESSMENT; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; HUMAN; MUCINOUS CARCINOMA; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CA-125 ANTIGEN; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 63449109983     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24152     Document Type: Review

References (28)

1. Rustin GJ, Marples M, Nelstrop AE, et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19:4054-4057.
2. Rustin GJ, Timmers P, Nelstrop A, et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol. 2006;24:45-51.
3. Bridgewater JA, Nelstrop AE, Rustin GJ, et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 1999;17:501-508.
4. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92:1534-1535.
5. Vergote IB, Bormer OP, Abeler VM. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol. 1987;157:88-92.
6. Makar AP, Kristensen GB, Bormer OP, et al. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol. 1993;49:73-79.
7. Peters-Engl C, Obermair A, Heinzl H, et al. CA 125 regression after 2 completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer. 1999;81:662-666.
8. Markman M, Liu PY, Rothenberg ML, et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006;24:1454-1458.
9. Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA- 125 levels within the normal range. JClin Oncol. 2005;23:9338-9343.
10. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophos-phamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
11. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007.
12. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18:106-115.
13. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351:2489-2497.
14. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin
15. Oncol. 2003;21:3194-3200.
16. Armstrong D, Bundy BN, Walker J, et al. A phase III randomized trial of intravenous paclitaxel and cisplatin versus intravenous paclitaxel, intraperitoneal cisplatin and in- traperitoneal paclitaxel in patients with optimal stage III epithelial ovarian carcinoma or primary peritoneal carcinoma. N Engl JMed. 2006;354:34-43.
17. Spriggs DR, Brady MF, Rubin S, et al. A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162). J Clin Oncol. 2007;25:4466-4471.
18. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology experience. J Clin Oncol. 1991;9:1138-1150.
19. Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2007;25:3621-3627.
20. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005;97:436-441.
21. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-1044.
22. Goff BA, Sainz de la CR, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60:412-417.
23. Crotzer DR, Sun CC, Coleman RL, et al. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007;105:404-408.
24. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004;10:3291-3300.
25. Hogdall EV, Christensen L, Kjaer SK, et al. CA-125 expression pattern, prognosis and correlation with serum CA-125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol. 2007; 104:508-515.
26. Redman JR, Petroni GR, Saigo PE, Geller NL, Hakes TB. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol. 1986;4:515-523.
27. Eisenkop SM, Friedman RL, Wang HJ. Complete cytore- ductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103-108.
28. Zorn KK, Armstrong DK, Tian C, et al. Significance of pretreatment CA-125 level in advanced ovarian carcinoma: a meta-analysis of 7 Gynecologic Oncology Group protocols [abstract]. Gynecol Oncol. 2007;104:S3.